

In the claims:

Please cancel claims 1-23 and 32-72 and amend claims 24, 26, 27, 28, 29, and 31 as follows:

24. (Amended) The use of a modified integrin I-domain polypeptide stabilized in the open conformation as an assay reagent to identify an antibody that selectively binds to an integrin I-domain in the open conformation.

26. (Amended) The antibody of claim 25, or an antigen binding fragment thereof, which binds to an activation specific epitope on the integrin I-domain.

27. (Amended) The antibody of claim 25, or an antigen binding fragment thereof, which blocks an interaction between an integrin and a cognate ligand.

28. (Amended) The antibody of claim 25, or an antigen binding fragment thereof, further comprising a pharmaceutical composition and a pharmaceutically acceptable carrier.

29. (Amended) The antibody of claim 25, or an antigen binding fragment thereof, wherein said antibody is an anti-LFA-1 antibody.

31. (Amended) The anti-LFA-1 antibody of claim 30, or an antigen binding fragment thereof, wherein said anti-LFA-1 antibody, or an antigen binding fragment thereof, selectively binds to a modified LFA-1 I-domain.

Please add new claims 73-75 as follows:

73. (New) The antibody of claim 25, or an antigen binding fragment thereof, wherein said antibody, or antigen binding fragment thereof, selectively binds to a modified I-domain of an α L subunit.

74. (New) The antibody of claim 73, or an antigen binding fragment thereof, wherein said modified I-domain of an α L subunit contains amino acid substitutions K287C/K294C or E284C/E301C.

75. (New) The anti-LFA-1 antibody of claim 31, or an antigen binding fragment thereof, wherein said anti-LFA-1 antibody, or an antigen binding fragment thereof selectively binds to a modified LFA-1 I-domain, wherein said modified LFA-1 I-domain contains amino acid substitutions K287C/K294C or E284C/E301C.

*Ad
Concl*